Home » Dr. Susan Blaney named vice-chair of the Children’s Oncology Group
Dr. Susan Blaney will serve in this position for five years and her responsibilities will include the timely development and implementation of innovative clinical and translational research protocols for children with cancer.
January 18, 2011 – Texas Children’s Hospital
With the unanimous endorsement of the Children’s Oncology Group (COG) Executive Committee, Dr. Susan Blaney has been named the vice-chair of the COG effective Jan. 1, 2011.
Blaney will serve in this position for five years and her responsibilities will include the timely development and implementation of innovative clinical and translational research protocols for children with cancer. The National Cancer Institute (NCI)-funded COG is an international clinical trial consortium of more than 220 institutions and is the largest childhood cancer research network in the country. Its goal is to prevent and cure childhood cancer through scientific discovery and compassionate care.
Blaney is the deputy director of Texas Children’s Cancer Center and holds numerous positions at Baylor College of Medicine including professor and vice chair for research in the department of pediatrics, associate director for clinical research of the Dan L. Duncan Cancer Center and co-director of The Institute for Clinical and Translational Research.
“It was truly an honor to be appointed vice-chair of the COG and I’m excited about working with researchers from around the country and internationally in support of the COG’s mission,” says Blaney. “Over the past several decades, cooperative research groups like the COG have improved overall survival rates for childhood cancer from less than 10 percent to nearly 80 percent. Through the COG and the ongoing collaboration of physicians and scientists we can continue to improve the outcome for all children with cancer.”
Blaney currently serves as the chair of developmental therapeutics for the COG, as well as the chair for the COG’s Phase I and Pilot Consortium. Additionally, Blaney is a member of the NCI’s Investigational Drug Steering Committee and serves on its Coordinating Committee.
Among Blaney’s numerous accomplishments, she serves as a consultant for the FDA’s Oncology Drug Advisory Committee and has been published in more than 150 peer-reviewed journal articles.